|
US4851332A
(en)
|
1985-04-01 |
1989-07-25 |
Sloan-Kettering Institute For Cancer Research |
Choriocarcinoma monoclonal antibodies and antibody panels
|
|
US5906936A
(en)
|
1988-05-04 |
1999-05-25 |
Yeda Research And Development Co. Ltd. |
Endowing lymphocytes with antibody specificity
|
|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
|
US6319494B1
(en)
|
1990-12-14 |
2001-11-20 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
|
WO1992010591A1
(en)
|
1990-12-14 |
1992-06-25 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
|
US7049136B2
(en)
|
1991-03-07 |
2006-05-23 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
|
US6004811A
(en)
|
1991-03-07 |
1999-12-21 |
The Massachussetts General Hospital |
Redirection of cellular immunity by protein tyrosine kinase chimeras
|
|
IE920716A1
(en)
|
1991-03-07 |
1992-09-09 |
Gen Hospital Corp |
Redirection of cellular immunity by receptor chimeras
|
|
US8211422B2
(en)
|
1992-03-18 |
2012-07-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric receptor genes and cells transformed therewith
|
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
|
US5646253A
(en)
|
1994-03-08 |
1997-07-08 |
Memorial Sloan-Kettering Cancer Center |
Recombinant human anti-LK26 antibodies
|
|
US7211259B1
(en)
|
1993-05-07 |
2007-05-01 |
Immunex Corporation |
4-1BB polypeptides and DNA encoding 4-1BB polypeptides
|
|
DE69528894T2
(de)
|
1994-05-02 |
2003-03-27 |
Bernd Groner |
Bifunktionelles protein, herstellung und verwendung
|
|
US5712149A
(en)
|
1995-02-03 |
1998-01-27 |
Cell Genesys, Inc. |
Chimeric receptor molecules for delivery of co-stimulatory signals
|
|
US6103521A
(en)
|
1995-02-06 |
2000-08-15 |
Cell Genesys, Inc. |
Multispecific chimeric receptors
|
|
ATE297986T1
(de)
|
1995-02-24 |
2005-07-15 |
Gen Hospital Corp |
Neuorientierung der zellulären immunität durch rezeptorchimären
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
GB9526131D0
(en)
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Recombinant chimeric receptors
|
|
US6177078B1
(en)
|
1995-12-29 |
2001-01-23 |
Medvet Science Pty Limited |
Monoclonal antibody antagonists to IL-3
|
|
US5874240A
(en)
|
1996-03-15 |
1999-02-23 |
Human Genome Sciences, Inc. |
Human 4-1BB receptor splicing variant
|
|
EP0938557B1
(en)
|
1996-10-25 |
2000-09-13 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Methods and compositions for inhibiting inflammation and angiogenesis comprising a mammalian cd97 alpha subunit
|
|
EP0937095A4
(en)
|
1996-10-25 |
1999-12-22 |
Cell Genesys Inc |
TARGETED CYTOLYSIS OF CANCER CELLS
|
|
EP1958962A3
(en)
|
1997-06-12 |
2013-05-01 |
Novartis International Pharmaceutical Ltd. |
Artificial antibody polypeptides
|
|
US20030060444A1
(en)
|
1997-06-25 |
2003-03-27 |
Celltech Therapeutics, Ltd. |
Cell activation process and reagents therefor
|
|
GB9713473D0
(en)
|
1997-06-25 |
1997-09-03 |
Celltech Therapeutics Ltd |
Biological products
|
|
GB9809658D0
(en)
|
1998-05-06 |
1998-07-01 |
Celltech Therapeutics Ltd |
Biological products
|
|
EP1109921A4
(en)
|
1998-09-04 |
2002-08-28 |
Sloan Kettering Inst Cancer |
FUSION RECEPTORS SPECIFIC TO MEMBRANE SPECIFIC PROSTATIC ANTIGEN AND USES THEREOF
|
|
JP2002535959A
(ja)
*
|
1998-10-19 |
2002-10-29 |
アリアド ジーン セラピューティクス インコーポレイテッド |
条件保持ドメインを含む材料および方法
|
|
US6410319B1
(en)
|
1998-10-20 |
2002-06-25 |
City Of Hope |
CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
|
|
WO2000063374A1
(en)
|
1999-04-16 |
2000-10-26 |
Celltech Therapeutics Limited |
Synthetic transmembrane components
|
|
CN100447244C
(zh)
|
1999-08-17 |
2008-12-31 |
比奥根艾迪克Ma公司 |
Baff受体(bcma),一种免疫调节剂
|
|
GB9925848D0
(en)
|
1999-11-01 |
1999-12-29 |
Celltech Therapeutics Ltd |
Biological products
|
|
US7262005B1
(en)
|
2000-02-04 |
2007-08-28 |
Aurora Biosciences Corporation |
Methods of protein destabilization and uses thereof
|
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
|
NZ521255A
(en)
|
2000-03-06 |
2007-01-26 |
Univ Kentucky Res Found |
Methods to impair hematologic cancer progenitor cells and compounds related thereto
|
|
IL136511A0
(en)
|
2000-06-01 |
2001-06-14 |
Gavish Galilee Bio Appl Ltd |
Genetically engineered mhc molecules
|
|
GB0025307D0
(en)
|
2000-10-16 |
2000-11-29 |
Celltech Chiroscience Ltd |
Biological products
|
|
ATE338124T1
(de)
|
2000-11-07 |
2006-09-15 |
Hope City |
Cd19-spezifische umgezielte immunzellen
|
|
WO2002066516A2
(en)
|
2001-02-20 |
2002-08-29 |
Zymogenetics, Inc. |
Antibodies that bind both bcma and taci
|
|
US7320991B2
(en)
|
2001-02-27 |
2008-01-22 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health |
Analogs of thalidomide as potential angiogenesis inhibitors
|
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
|
CN1294148C
(zh)
|
2001-04-11 |
2007-01-10 |
中国科学院遗传与发育生物学研究所 |
环状单链三特异抗体
|
|
US20090257994A1
(en)
|
2001-04-30 |
2009-10-15 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
|
US7514537B2
(en)
|
2001-04-30 |
2009-04-07 |
City Of Hope |
Chimeric immunoreceptor useful in treating human gliomas
|
|
WO2002088334A1
(en)
|
2001-04-30 |
2002-11-07 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
|
US20030148982A1
(en)
|
2001-11-13 |
2003-08-07 |
Brenner Malcolm K. |
Bi-spcific chimeric T cells
|
|
WO2003057171A2
(en)
|
2002-01-03 |
2003-07-17 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of t-cells using an engineered multivalent signaling platform
|
|
US7745140B2
(en)
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
|
US7638326B2
(en)
|
2002-01-03 |
2009-12-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
US20050129671A1
(en)
|
2003-03-11 |
2005-06-16 |
City Of Hope |
Mammalian antigen-presenting T cells and bi-specific T cells
|
|
WO2004087758A2
(en)
|
2003-03-26 |
2004-10-14 |
Neopharm, Inc. |
Il 13 receptor alpha 2 antibody and methods of use
|
|
KR20060041205A
(ko)
|
2003-07-01 |
2006-05-11 |
이뮤노메딕스, 인코오포레이티드 |
양특이성 항체들의 다가 담체들
|
|
WO2005019429A2
(en)
|
2003-08-22 |
2005-03-03 |
Potentia Pharmaceuticals, Inc. |
Compositions and methods for enhancing phagocytosis or phagocyte activity
|
|
US7973057B2
(en)
|
2003-09-17 |
2011-07-05 |
The United States Of America As Represented By The Department Of Health And Human Services |
Thalidomide analogs
|
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
|
US20050113564A1
(en)
|
2003-11-05 |
2005-05-26 |
St. Jude Children's Research Hospital |
Chimeric receptors with 4-1BB stimulatory signaling domain
|
|
WO2005118788A2
(en)
|
2004-05-27 |
2005-12-15 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses therefor
|
|
EP1786918A4
(en)
|
2004-07-17 |
2009-02-11 |
Imclone Systems Inc |
NEW BISPECIFIC ANTIBODY TETRAVALENT
|
|
US7994298B2
(en)
|
2004-09-24 |
2011-08-09 |
Trustees Of Dartmouth College |
Chimeric NK receptor and methods for treating cancer
|
|
WO2006060878A1
(en)
|
2004-12-10 |
2006-06-15 |
Peter Maccallum Cancer Institute |
Methods and compositions for adoptive immunotherapy
|
|
EP1726650A1
(en)
|
2005-05-27 |
2006-11-29 |
Universitätsklinikum Freiburg |
Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
|
|
US20070036773A1
(en)
|
2005-08-09 |
2007-02-15 |
City Of Hope |
Generation and application of universal T cells for B-ALL
|
|
NZ612578A
(en)
|
2005-08-19 |
2014-11-28 |
Abbvie Inc |
Dual variable domain immunoglobin and uses thereof
|
|
CA2646329C
(en)
|
2006-03-20 |
2018-07-03 |
The Regents Of The University Of California |
Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
|
|
TWI395754B
(zh)
|
2006-04-24 |
2013-05-11 |
Amgen Inc |
人類化之ｃ-ｋｉｔ抗體
|
|
AU2007304590A1
(en)
|
2006-10-04 |
2008-04-10 |
Cancer Research Technology Limited |
Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies
|
|
WO2008045437A2
(en)
|
2006-10-09 |
2008-04-17 |
The General Hospital Corporation |
Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
|
|
FR2906808B1
(fr)
|
2006-10-10 |
2012-10-05 |
Univ Nantes |
Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers
|
|
US20080131415A1
(en)
|
2006-11-30 |
2008-06-05 |
Riddell Stanley R |
Adoptive transfer of cd8 + t cell clones derived from central memory cells
|
|
US8173792B2
(en)
|
2007-02-09 |
2012-05-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
Method for regulating protein function in cells using synthetic small molecules
|
|
WO2008103645A2
(en)
|
2007-02-19 |
2008-08-28 |
Wisconsin Alumni Research Foundation |
Prostate cancer and melanoma antigens
|
|
SI2856876T1
(en)
|
2007-03-30 |
2018-04-30 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
|
|
US8163279B2
(en)
|
2007-04-13 |
2012-04-24 |
Stemline Therapeutics, Inc. |
IL3Rα antibody conjugates and uses thereof
|
|
JP2010190572A
(ja)
|
2007-06-01 |
2010-09-02 |
Sapporo Medical Univ |
ＩＬ１３Ｒａ２に対する抗体およびこれを含む診断・治療薬
|
|
WO2009091826A2
(en)
|
2008-01-14 |
2009-07-23 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
|
|
WO2009097140A1
(en)
|
2008-01-30 |
2009-08-06 |
Memorial Sloan-Kettering Cancer Center |
Methods for off -the -shelf tumor immunotherapy using allogeneic t-cell precursors
|
|
US8379824B2
(en)
|
2008-03-06 |
2013-02-19 |
At&T Intellectual Property I, Lp |
Methods and apparatus to provide a network-based caller identification service in a voice over internet protocol network
|
|
EP2331566B1
(en)
|
2008-08-26 |
2015-10-07 |
City of Hope |
Method and compositions for enhanced anti-tumor effector functioning of t cells
|
|
WO2010085660A2
(en)
|
2009-01-23 |
2010-07-29 |
Roger Williams Hospital |
Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same
|
|
MX341884B
(es)
|
2009-03-10 |
2016-09-07 |
Biogen Ma Inc |
Anticuerpos anti-antigeno de maduracion de celulas b (bcma).
|
|
JP5694923B2
(ja)
|
2009-04-27 |
2015-04-01 |
協和発酵キリン株式会社 |
血液腫瘍治療を目的とした抗ＩＬ−３Ｒα抗体
|
|
CA2776143A1
(en)
|
2009-10-01 |
2011-04-07 |
The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services |
Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
|
|
CA2774871C
(en)
|
2009-10-20 |
2018-05-29 |
Tokyo Institute Of Technology |
Screening method utilizing thalidomide-targeting factor
|
|
WO2011059836A2
(en)
|
2009-10-29 |
2011-05-19 |
Trustees Of Dartmouth College |
T cell receptor-deficient t cell compositions
|
|
AU2010325969B2
(en)
|
2009-12-02 |
2016-10-20 |
Imaginab, Inc. |
J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen
|
|
ES2724451T3
(es)
|
2010-02-04 |
2019-09-11 |
Univ Pennsylvania |
ICOS regula fundamentalmente la expansión y la función de linfocitos Th17 humanos inflamatorios
|
|
TWI622402B
(zh)
|
2010-02-24 |
2018-05-01 |
免疫遺傳股份有限公司 |
葉酸受體１抗體類和免疫共軛物類及彼等之用途
|
|
RS56042B1
(sr)
|
2010-06-10 |
2017-09-29 |
Seragon Pharmaceuticals Inc |
Modulatori estrogenih receptora i njihove upotrebe
|
|
US8853423B2
(en)
|
2010-06-17 |
2014-10-07 |
Seragon Pharmaceuticals, Inc. |
Indane estrogen receptor modulators and uses thereof
|
|
EP3323830B1
(en)
|
2010-06-19 |
2023-08-23 |
Memorial Sloan-Kettering Cancer Center |
Anti-gd2 antibodies
|
|
WO2012033885A1
(en)
|
2010-09-08 |
2012-03-15 |
Baylor College Of Medicine |
Immunotherapy of cancer using genetically engineered gd2-specific t cells
|
|
MX2013004792A
(es)
|
2010-10-27 |
2013-08-27 |
Baylor College Medicine |
Receptor cd27 quimericos para redirigir celulas t a malignidades cd70-positivas.
|
|
EP3974453A3
(en)
|
2010-11-16 |
2022-08-03 |
Amgen Inc. |
Agents and methods for treating diseases that correlate with bcma expression
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
US9233125B2
(en)
|
2010-12-14 |
2016-01-12 |
University Of Maryland, Baltimore |
Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer
|
|
KR20140004174A
(ko)
|
2011-01-18 |
2014-01-10 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
암 치료를 위한 조성물 및 방법
|
|
WO2012127464A2
(en)
|
2011-03-23 |
2012-09-27 |
Gavish-Galilee Bio Applications Ltd |
Constitutively activated t cells for use in adoptive cell therapy
|
|
US9987308B2
(en)
|
2011-03-23 |
2018-06-05 |
Fred Hutchinson Cancer Research Center |
Method and compositions for cellular immunotherapy
|
|
MX2013011363A
(es)
|
2011-04-01 |
2014-04-25 |
Sloan Kettering Inst Cancer |
Anticuerpos para peptidos citosolicos.
|
|
CA2832569A1
(en)
|
2011-04-08 |
2012-10-11 |
Baylor College Of Medicine |
Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
|
|
CA2832540C
(en)
|
2011-04-08 |
2020-09-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
|
|
US20130101599A1
(en)
|
2011-04-21 |
2013-04-25 |
Boehringer Ingelheim International Gmbh |
Bcma-based stratification and therapy for multiple myeloma patients
|
|
US20130071414A1
(en)
|
2011-04-27 |
2013-03-21 |
Gianpietro Dotti |
Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
|
|
AR086044A1
(es)
|
2011-05-12 |
2013-11-13 |
Imclone Llc |
Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
|
|
KR101972446B1
(ko)
|
2011-05-27 |
2019-04-25 |
글락소 그룹 리미티드 |
Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）결합 단백질
|
|
UA112434C2
(uk)
|
2011-05-27 |
2016-09-12 |
Ґлаксо Ґруп Лімітед |
Антигензв'язувальний білок, який специфічно зв'язується з всма
|
|
EP2736539B1
(en)
|
2011-07-25 |
2017-08-23 |
Nationwide Children's Hospital, Inc. |
Recombinant virus products and methods for inhibition of expression of dux4
|
|
MX2014001222A
(es)
|
2011-07-29 |
2014-09-15 |
Univ Pennsylvania |
Receptores coestimuladores de cambio.
|
|
WO2013033626A2
(en)
|
2011-08-31 |
2013-03-07 |
Trustees Of Dartmouth College |
Nkp30 receptor targeted therapeutics
|
|
EP3326467B1
(en)
|
2011-09-16 |
2020-03-11 |
Baylor College of Medicine |
Targeting the tumor microenvironment using manipulated nkt cells
|
|
CN103946952A
(zh)
|
2011-09-16 |
2014-07-23 |
宾夕法尼亚大学董事会 |
用于治疗癌症的rna改造的t细胞
|
|
ES2654060T3
(es)
|
2011-10-20 |
2018-02-12 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Receptores de antígenos quiméricos anti-CD22
|
|
ITMO20110270A1
(it)
|
2011-10-25 |
2013-04-26 |
Sara Caldrer |
Una cellula effettrice modificata per il trattamento di neoplasie esprimenti il disialonganglioside gd2
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
US10391126B2
(en)
|
2011-11-18 |
2019-08-27 |
Board Of Regents, The University Of Texas System |
CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
|
|
US9439768B2
(en)
|
2011-12-08 |
2016-09-13 |
Imds Llc |
Glenoid vault fixation
|
|
WO2013090829A1
(en)
|
2011-12-14 |
2013-06-20 |
Aragon Pharmaceuticals, Inc. |
Estrogen receptor modulators and uses thereof
|
|
EP2791128A4
(en)
|
2011-12-16 |
2015-04-22 |
Olema Pharmaceuticals Inc |
NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF
|
|
CA2861491C
(en)
|
2012-02-13 |
2020-08-25 |
Seattle Children's Hospital D/B/A Seattle Children's Research Institute |
Bispecific chimeric antigen receptors and therapeutic uses thereof
|
|
WO2013126729A1
(en)
|
2012-02-22 |
2013-08-29 |
The Trustees Of The University Of Pennsylvania |
Use of the cd2 signaling domain in second-generation chimeric antigen receptors
|
|
CA3285826A1
(en)
|
2012-02-22 |
2026-03-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
|
|
EP2817330B1
(en)
|
2012-02-22 |
2020-07-08 |
The Trustees of the University of Pennsylvania |
Use of icos-based cars to enhance antitumor activity and car persistence
|
|
WO2013151649A1
(en)
|
2012-04-04 |
2013-10-10 |
Sialix Inc |
Glycan-interacting compounds
|
|
RU2766608C2
(ru)
|
2012-04-11 |
2022-03-15 |
Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез |
Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
|
|
JP6509724B2
(ja)
|
2012-04-20 |
2019-05-08 |
アプティーボ リサーチ アンド デベロップメント エルエルシー |
Ｃｄ３結合ポリペプチド
|
|
PT2850106T
(pt)
|
2012-05-18 |
2022-07-18 |
Aptevo Res & Development Llc |
Imunofusão biespecífica (bif) de scfv de ligação a cd123 e cd3
|
|
WO2013192294A1
(en)
|
2012-06-20 |
2013-12-27 |
Boston 3T Biotechnologies, Inc. |
Cellular therapies for treating and preventing cancers and other immune system disorders
|
|
ES2872967T3
(es)
*
|
2012-06-29 |
2021-11-03 |
Celgene Corp |
Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS)
|
|
JP2015524255A
(ja)
|
2012-07-13 |
2015-08-24 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
二重特異性抗体を共導入することによってｃａｒｔ細胞の活性を強化する方法
|
|
HRP20230297T1
(hr)
|
2012-07-13 |
2023-05-12 |
The Trustees Of The University Of Pennsylvania |
UPRAVLJANJE TOKSIČNOŠĆU ZA ANTI-TUMORSKO DJELOVANJE CAR-a
|
|
JP6482461B2
(ja)
|
2012-07-13 |
2019-03-13 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
投与に関する形質導入ｔ細胞の適合性の評価方法
|
|
US20150290244A1
(en)
|
2012-07-13 |
2015-10-15 |
The Trustees Of The University Of Pennsylvania |
Use of cart19 to deplete normal b cells to induce tolerance
|
|
US20150140019A1
(en)
|
2012-07-13 |
2015-05-21 |
The Trustees Of The University Of Pennsylvania |
Compositions and Methods for Regulating CAR T Cells
|
|
EP2872617A4
(en)
|
2012-07-13 |
2015-12-09 |
Univ Pennsylvania |
EPITOP SPREADING IN CONNECTION WITH CAR T CELLS
|
|
JP6024953B2
(ja)
*
|
2012-07-25 |
2016-11-16 |
国立大学法人 岡山大学 |
Ｐｉｎｋ１のユビキチン化アッセイ及びスクリーニングへの利用
|
|
BR122020002986A8
(pt)
|
2012-08-20 |
2023-04-18 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Método e composições para imunoterapia celular
|
|
WO2014039513A2
(en)
|
2012-09-04 |
2014-03-13 |
The Trustees Of The University Of Pennsylvania |
Inhibition of diacylglycerol kinase to augment adoptive t cell transfer
|
|
US20140090111A1
(en)
*
|
2012-09-05 |
2014-03-27 |
Carnegie Institution Of Washington |
Plant Hormone Biosensors
|
|
WO2014055442A2
(en)
|
2012-10-01 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
|
WO2014055657A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
|
WO2014068079A1
(en)
|
2012-11-01 |
2014-05-08 |
Max-Delbrück-Centrum für Molekulare Medizin |
An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
|
|
US9243058B2
(en)
|
2012-12-07 |
2016-01-26 |
Amgen, Inc. |
BCMA antigen binding proteins
|
|
WO2014122143A1
(en)
|
2013-02-05 |
2014-08-14 |
Engmab Ag |
Method for the selection of antibodies against bcma
|
|
US9573988B2
(en)
|
2013-02-20 |
2017-02-21 |
Novartis Ag |
Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
|
|
JP6647868B2
(ja)
|
2013-02-20 |
2020-02-14 |
ノバルティス アーゲー |
ヒト化抗ＥＧＦＲｖＩＩＩキメラ抗原受容体を用いたがんの処置
|
|
US20160046718A1
(en)
|
2013-03-14 |
2016-02-18 |
Csl Limited |
Agents that neutralize il-3 signalling and uses thereof
|
|
WO2014138805A1
(en)
|
2013-03-14 |
2014-09-18 |
Csl Limited |
Anti il-3r alpha agents and uses thereof
|
|
AR095374A1
(es)
|
2013-03-15 |
2015-10-14 |
Amgen Res Munich Gmbh |
Moléculas de unión para bcma y cd3
|
|
US9657105B2
(en)
|
2013-03-15 |
2017-05-23 |
City Of Hope |
CD123-specific chimeric antigen receptor redirected T cells and methods of their use
|
|
WO2014145252A2
(en)
|
2013-03-15 |
2014-09-18 |
Milone Michael C |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
WO2015172800A1
(en)
|
2014-05-12 |
2015-11-19 |
Numab Ag |
Novel multispecific molecules and novel treatment methods based on such multispecific molecules
|
|
CA2913052A1
(en)
|
2013-05-24 |
2014-11-27 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptor-targeting monoclonal antibodies
|
|
UY35590A
(es)
|
2013-05-28 |
2014-11-28 |
Astrazeneca Ab |
Nuevos compuestos para el tratamiento del cáncer
|
|
WO2014203132A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Substituted benzopyran compounds, compositions and uses thereof
|
|
WO2014203129A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Combinations of benzopyran compounds, compositions and uses thereof
|
|
CA2915534A1
(en)
|
2013-06-19 |
2014-12-24 |
Seragon Pharmaceuticals, Inc. |
Azetidine estrogen receptor modulators and uses thereof
|
|
EA031077B1
(ru)
|
2013-06-19 |
2018-11-30 |
Серагон Фармасьютикалз, Инк. |
Модулятор рецептора эстрогена и его применения
|
|
US20160282354A1
(en)
*
|
2013-11-08 |
2016-09-29 |
The Broad Institute, Inc. |
Compositions and methods for selecting a treatment for b-cell neoplasias
|
|
ES2918501T3
(es)
|
2013-12-19 |
2022-07-18 |
Novartis Ag |
Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
|
|
EP3087101B1
(en)
|
2013-12-20 |
2024-06-05 |
Novartis AG |
Regulatable chimeric antigen receptor
|
|
WO2015112626A1
(en)
|
2014-01-21 |
2015-07-30 |
June Carl H |
Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
|
|
AU2015214145A1
(en)
|
2014-02-04 |
2016-08-25 |
Kite Pharma. Inc. |
Methods for producing autologous T cells useful to treat B cell malignancies and other cancers and compositions thereof
|
|
US10272117B2
(en)
|
2014-02-24 |
2019-04-30 |
Celgene Corporation |
Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
|
|
EP3114217A4
(en)
|
2014-03-07 |
2017-09-20 |
Bellicum Pharmaceuticals, Inc. |
Caspase polypeptides having modified activity and uses thereof
|
|
ES2857226T3
(es)
|
2014-03-15 |
2021-09-28 |
Novartis Ag |
Receptor de antígeno quimérico regulable
|
|
US20170335281A1
(en)
|
2014-03-15 |
2017-11-23 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
|
AU2015244039B2
(en)
|
2014-04-07 |
2021-10-21 |
Novartis Ag |
Treatment of cancer using anti-CD19 chimeric antigen receptor
|
|
RU2738833C9
(ru)
*
|
2014-04-14 |
2022-02-28 |
Арвинас, Оперэйшнз, Инк. |
Имидные модуляторы протеолиза и способы их применения
|
|
EP3131927B8
(en)
|
2014-04-14 |
2020-12-23 |
Cellectis |
Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
|
|
PL3134432T3
(pl)
|
2014-04-25 |
2020-10-19 |
Bluebird Bio, Inc. |
Promotor mnd chimeryczne receptory antygenowe
|
|
HUE049514T2
(hu)
|
2014-04-25 |
2020-09-28 |
Bluebird Bio Inc |
Javított eljárások adoptív sejtterápiák kialakítására
|
|
KR102526945B1
(ko)
|
2014-04-30 |
2023-04-27 |
막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 |
Ｃｄ269에 대한 인간화 항체
|
|
CN113604491A
(zh)
|
2014-05-02 |
2021-11-05 |
宾夕法尼亚大学董事会 |
嵌合自身抗体受体t细胞的组合物和方法
|
|
SI3151672T1
(sl)
|
2014-06-06 |
2021-03-31 |
Bluebird Bio, Inc. |
Izboljšani T-celični sestavki
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
US20170226495A1
(en)
|
2014-07-21 |
2017-08-10 |
Novartis Ag |
Sortase molecules and uses thereof
|
|
US20170274014A1
(en)
|
2014-07-21 |
2017-09-28 |
Jennifer Brogdon |
Combinations of low, immune enhancing, doses of mtor inhibitors and cars
|
|
SG10201913782UA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cll-1 chimeric antigen receptor
|
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
|
|
TWI719942B
(zh)
|
2014-07-21 |
2021-03-01 |
瑞士商諾華公司 |
使用ｃｄ３３嵌合抗原受體治療癌症
|
|
BR112017001183A2
(pt)
|
2014-07-21 |
2017-11-28 |
Novartis Ag |
tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
|
|
ES2878449T3
(es)
|
2014-07-24 |
2021-11-18 |
2Seventy Bio Inc |
Receptores antigénicos quiméricos de BCMA
|
|
EP4205749A1
(en)
|
2014-07-31 |
2023-07-05 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing cells
|
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
AU2015301460B2
(en)
|
2014-08-14 |
2021-04-08 |
Novartis Ag |
Treatment of cancer using GFR alpha-4 chimeric antigen receptor
|
|
MX2017002205A
(es)
|
2014-08-19 |
2017-08-21 |
Novartis Ag |
Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
|
|
JP6839074B2
(ja)
|
2014-09-17 |
2021-03-03 |
ノバルティス アーゲー |
養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
|
|
KR20170068504A
(ko)
|
2014-10-08 |
2017-06-19 |
노파르티스 아게 |
키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
|
|
AU2015330730A1
(en)
*
|
2014-10-10 |
2017-04-13 |
Dana-Farber Cancer Institute, Inc. |
Plasmids comprising internal ribosomal entry sites and uses thereof
|
|
WO2016061368A1
(en)
|
2014-10-15 |
2016-04-21 |
The Children's Hospital Of Philadelphia |
Compositions and methods for treating b-lymphoid malignancies
|
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
EP3029068A1
(en)
|
2014-12-03 |
2016-06-08 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
|
|
SI3226897T1
(sl)
|
2014-12-05 |
2021-08-31 |
Memorial Sloan Kettering Cancer Center |
Protitelesa, ki ciljajo na B-celični maturacijski antigen, in postopki uporabe
|
|
MY191537A
(en)
|
2014-12-05 |
2022-06-30 |
Memorial Sloan Kettering Cancer Center |
Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
|
|
HRP20191873T1
(hr)
|
2014-12-12 |
2020-01-24 |
Bluebird Bio, Inc. |
Kimerni antigenski receptori
|
|
CA2970370A1
(en)
|
2014-12-24 |
2016-06-30 |
Massachusetts Institute Of Technology |
Crispr having or associated with destabilization domains
|
|
RU2021118125A
(ru)
|
2014-12-29 |
2022-04-06 |
Новартис Аг |
Способы получения экспрессирующих химерный антигенный рецептор клеток
|
|
US11459390B2
(en)
|
2015-01-16 |
2022-10-04 |
Novartis Ag |
Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
|
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
EP3256492A4
(en)
|
2015-02-09 |
2018-07-11 |
University of Florida Research Foundation, Inc. |
Bi-specific chimeric antigen receptor and uses thereof
|
|
WO2016154055A1
(en)
|
2015-03-20 |
2016-09-29 |
Bluebird Bio, Inc. |
Vector formulations
|
|
ES2876974T3
(es)
|
2015-04-07 |
2021-11-15 |
Novartis Ag |
Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
|
|
JP6961490B2
(ja)
|
2015-04-08 |
2021-11-05 |
ノバルティス アーゲー |
Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法
|
|
TWI703159B
(zh)
|
2015-04-13 |
2020-09-01 |
美商輝瑞股份有限公司 |
Bcma特異性治療性抗體及其用途
|
|
US10294304B2
(en)
|
2015-04-13 |
2019-05-21 |
Pfizer Inc. |
Chimeric antigen receptors targeting B-cell maturation antigen
|
|
AU2016249005B2
(en)
|
2015-04-17 |
2022-06-16 |
Novartis Ag |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
US11655452B2
(en)
|
2015-06-25 |
2023-05-23 |
Icell Gene Therapeutics Inc. |
Chimeric antigen receptors (CARs), compositions and methods of use thereof
|
|
US10550379B2
(en)
|
2015-06-29 |
2020-02-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
Degron fusion constructs and methods for controlling protein production
|
|
US9914777B2
(en)
|
2015-07-10 |
2018-03-13 |
Merus N.V. |
Human CD3 binding antibody
|
|
EP3322735A4
(en)
|
2015-07-15 |
2019-03-13 |
Zymeworks Inc. |
ACTIVE CONJUGATED BIS-SPECIFIC ANTIGEN-BONDING CONSTRUCTS
|
|
HK1255161A1
(zh)
|
2015-07-15 |
2019-08-09 |
Juno Therapeutics, Inc. |
用於过继性细胞治疗的工程细胞
|
|
CA2992551A1
(en)
|
2015-07-21 |
2017-01-26 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
|
SI3331910T1
(sl)
|
2015-08-03 |
2020-07-31 |
Engmab Sarl |
Monoklonska protitelesa proti humani antigen dozorevanja limfocitov B (BCMA)
|
|
WO2017024318A1
(en)
*
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
|
US11667691B2
(en)
|
2015-08-07 |
2023-06-06 |
Novartis Ag |
Treatment of cancer using chimeric CD3 receptor proteins
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
MX2018002043A
(es)
|
2015-08-17 |
2018-07-06 |
Janssen Pharmaceutica Nv |
ANTICUERPOS ANTI-BCMA, MOLíCULAS DE UNIíN A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS.
|
|
EP3341410B1
(en)
|
2015-08-24 |
2021-06-02 |
Cellectis |
Chimeric antigen receptors with integrated controllable functions
|
|
WO2017040930A2
(en)
|
2015-09-03 |
2017-03-09 |
The Trustees Of The University Of Pennsylvania |
Biomarkers predictive of cytokine release syndrome
|
|
US11168345B2
(en)
*
|
2015-09-11 |
2021-11-09 |
The Broad Institute, Inc. |
Methods of identifying a polypeptide target for degradation by a modulator of CRBN
|
|
AU2016323985B2
(en)
|
2015-09-17 |
2022-12-15 |
Novartis Ag |
CAR T cell therapies with enhanced efficacy
|
|
AU2016330967B2
(en)
|
2015-09-30 |
2021-03-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Thalidomide analogs and methods of use
|
|
EP4643874A3
(en)
|
2015-12-22 |
2026-02-11 |
Novartis AG |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
|
CN109153975A
(zh)
|
2015-12-28 |
2019-01-04 |
诺华股份有限公司 |
制备嵌合抗原受体表达细胞的方法
|
|
RU2018127657A
(ru)
|
2015-12-30 |
2020-01-31 |
Новартис Аг |
Виды терапии на основе иммуноэффекторных клеток с улучшенной эффективностью
|
|
KR20180118175A
(ko)
|
2016-03-04 |
2018-10-30 |
노파르티스 아게 |
다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도
|
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
|
CN109715808A
(zh)
|
2016-04-15 |
2019-05-03 |
诺华股份有限公司 |
用于选择性蛋白质表达的组合物和方法
|
|
WO2017210617A2
(en)
|
2016-06-02 |
2017-12-07 |
Porter, David, L. |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
|
SG11201900344YA
(en)
|
2016-07-15 |
2019-02-27 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
|
AU2017302668B9
(en)
|
2016-07-28 |
2023-06-22 |
Novartis Ag |
Combination therapies of chimeric antigen receptors and PD-1 inhibitors
|
|
BR112019002035A2
(pt)
|
2016-08-01 |
2019-05-14 |
Novartis Ag |
tratamento de câncer usando um receptor de antígeno quimérico em combinação com um inibidor de uma molécula pró-macrófago m2
|
|
US11340216B2
(en)
*
|
2016-09-13 |
2022-05-24 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the positive selection of protein destabilizers
|
|
JP2019532953A
(ja)
|
2016-09-30 |
2019-11-14 |
ノバルティス アーゲー |
増強された有効性を有する免疫エフェクター細胞治療
|
|
BR112019006781A2
(pt)
|
2016-10-07 |
2019-07-30 |
Novartis Ag |
receptores de antígeno quiméricos para o tratamento de câncer
|
|
JP7100028B2
(ja)
|
2016-10-20 |
2022-07-12 |
セルジーン コーポレイション |
セレブロン系のヘテロ二量体化可能なキメラ抗原受容体
|
|
ES2912408T3
(es)
|
2017-01-26 |
2022-05-25 |
Novartis Ag |
Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos
|
|
CN110582509A
(zh)
|
2017-01-31 |
2019-12-17 |
诺华股份有限公司 |
使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
|
|
AU2018219292B2
(en)
|
2017-02-08 |
2024-09-26 |
Dana-Farber Cancer Institute, Inc. |
Tunable endogenous protein degradation with heterobifunctional compounds
|
|
JP7227912B2
(ja)
|
2017-02-08 |
2023-02-24 |
ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド |
キメラ抗原受容体の調節
|
|
WO2018160731A1
(en)
|
2017-02-28 |
2018-09-07 |
Novartis Ag |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
CN110831619A
(zh)
|
2017-03-22 |
2020-02-21 |
诺华股份有限公司 |
具有增强功效的生物标志和car t细胞疗法
|
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
IT201700057500A1
(it)
*
|
2017-05-26 |
2018-11-26 |
Piaggio & C Spa |
Gruppo ammortizzatore di veicolo con blocco cinematico selettivo, gruppo sospensione di veicolo e relativo veicolo
|
|
GB201710620D0
(en)
*
|
2017-07-03 |
2017-08-16 |
Glaxosmithkline Intellectual Property Ltd |
Targeted protein degradation
|
|
AU2018351050B2
(en)
*
|
2017-10-18 |
2025-09-18 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
RU2020116579A
(ru)
|
2017-10-25 |
2021-11-25 |
Новартис Аг |
Способы получения клеток, экспрессирующих химерный антигенный рецептор
|
|
CN111787938A
(zh)
|
2017-11-15 |
2020-10-16 |
诺华股份有限公司 |
靶向bcma的嵌合抗原受体、靶向cd19的嵌合抗原受体及组合疗法
|
|
US20200371091A1
(en)
|
2017-11-30 |
2020-11-26 |
Novartis Ag |
Bcma-targeting chimeric antigen receptor, and uses thereof
|
|
US20200399383A1
(en)
|
2018-02-13 |
2020-12-24 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
US20200061113A1
(en)
|
2018-04-12 |
2020-02-27 |
Novartis Ag |
Chimeric antigen receptor therapy characterization assays and uses thereof
|
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
EP3788369A1
(en)
|
2018-05-01 |
2021-03-10 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
US20200085869A1
(en)
|
2018-05-16 |
2020-03-19 |
Novartis Ag |
Therapeutic regimens for chimeric antigen receptor therapies
|
|
EP3801769A1
(en)
|
2018-05-25 |
2021-04-14 |
Novartis AG |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
TWI890660B
(zh)
|
2018-06-13 |
2025-07-21 |
瑞士商諾華公司 |
Bcma 嵌合抗原受體及其用途
|
|
EP4635978A2
(en)
|
2018-08-31 |
2025-10-22 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
EP3844265A2
(en)
|
2018-08-31 |
2021-07-07 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
WO2020069409A1
(en)
|
2018-09-28 |
2020-04-02 |
Novartis Ag |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
|
WO2020069405A1
(en)
|
2018-09-28 |
2020-04-02 |
Novartis Ag |
Cd22 chimeric antigen receptor (car) therapies
|
|
US20220152150A1
(en)
|
2019-02-25 |
2022-05-19 |
Novartis Ag |
Mesoporous silica particles compositions for viral delivery
|
|
EP3942025A1
(en)
|
2019-03-21 |
2022-01-26 |
Novartis AG |
Car-t cell therapies with enhanced efficacy
|
|
EP3953455A1
(en)
|
2019-04-12 |
2022-02-16 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
EP3959320A1
(en)
|
2019-04-24 |
2022-03-02 |
Novartis AG |
Compositions and methods for selective protein degradation
|
|
EP4065157A1
(en)
|
2019-11-26 |
2022-10-05 |
Novartis AG |
Cd19 and cd22 chimeric antigen receptors and uses thereof
|
|
IL293215A
(en)
|
2019-11-26 |
2022-07-01 |
Novartis Ag |
Chimeric antigen receptors that bind bcma and cd19 and their uses
|
|
EP4104187A1
(en)
|
2020-02-14 |
2022-12-21 |
Novartis AG |
Method of predicting response to chimeric antigen receptor therapy
|
|
EP4110376A2
(en)
|
2020-02-27 |
2023-01-04 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
CN115397460A
(zh)
|
2020-02-27 |
2022-11-25 |
诺华股份有限公司 |
制备表达嵌合抗原受体的细胞的方法
|
|
JP2023529211A
(ja)
|
2020-06-11 |
2023-07-07 |
ノバルティス アーゲー |
Ｚｂｔｂ３２阻害剤及びその使用
|
|
MX2023002107A
(es)
|
2020-08-21 |
2023-03-15 |
Novartis Ag |
Composiciones y metodos para la generacion in vivo de celulas que expresan car.
|